IPO5 promotes malignant progression of esophageal cancer through activating MMP7.

OBJECTIVE Previous studies have found that IPO5 is a cancer-promoting gene. However, the role of IPO5 in esophageal cancer has not been reported. This study aims to investigate the expression characteristics of IPO5 in esophageal cancer, and to further analyze its relationship with clinical parameters and prognosis of esophageal cancer. PATIENTS AND METHODS Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was performed to examine the expression of matrix metalloproteinase 7 (MMP7) in 45 pairs of tumor tissue specimens and adjacent normal ones collected from esophageal cancer patients. The correlation between IPO5 expression and clinical indicators and prognosis of esophageal cancer patients was analyzed. Meanwhile, IPO5 expression in esophageal cancer cell lines was also detected using qRT-PCR. In addition, the influence of IPO5 on esophageal cancer cell functions was analyzed using cell counting kit-8 (CCK-8) and 5-Ethynyl-2'-deoxyuridine (EdU) assays. Finally, Dual-Luciferase reporter assay and cell reverse experiments were conducted to explore its underlying mechanisms. RESULTS In this experiment, qRT-PCR results indicated that IPO5 expression in tumor tissues of esophageal cancer patients was significantly higher than that in adjacent normal ones, and the difference was statistically significant. Compared with esophageal cancer patients with low expression of IPO5, those with high expression of IPO5 had higher pathological stage and lower overall survival rate. Compared with control group, the proliferation ability of esophageal cancer cells in IPO5 knockdown group was significantly decreased. In addition, Western Blot results indicated that the key protein MMP7 was conspicuously elevated in the esophageal cancer cell line after knockdown of IPO5. Dual-Luciferase reporter assay results suggested that IPO5 can specifically bind MMP7. Additionally, the cell reverse experiment demonstrated that MMP7 was responsible for IPO5-regulated malignant progression of esophageal cancer. CONCLUSIONS IPO5 expression significantly increased in esophageal cancer tissues, which was associated with pathological staging and poor prognosis of esophageal cancer patients. IPO5 may promote malignant progression of esophageal cancer through the regulation of MMP7.

[1]  M. Masoodi,et al.  Biological and clinical relevance of metastasis‐associated long noncoding RNAs in esophageal squamous cell carcinoma: A systematic review , 2020, Journal of cellular physiology.

[2]  Xinyi Liu,et al.  SREBP1 promotes the invasion of colorectal cancer accompanied upregulation of MMP7 expression and NF-κB pathway activation , 2019, BMC Cancer.

[3]  Jianming Zhang,et al.  IPO5 promotes the proliferation and tumourigenicity of colorectal cancer cells by mediating RASAL2 nuclear transportation , 2019, Journal of experimental & clinical cancer research : CR.

[4]  H. Matsubara,et al.  Imaging biomarkers for the treatment of esophageal cancer , 2019, World journal of gastroenterology.

[5]  Song-Qiang Xie,et al.  DKK1 inhibits breast cancer cell migration and invasion through suppression of β-catenin/MMP7 signaling pathway , 2019, Cancer Cell International.

[6]  J. Wagner,et al.  A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential , 2019, BMC Cancer.

[7]  Gautam K. Malhotra,et al.  Managing Squamous Cell Esophageal Cancer. , 2019, The Surgical clinics of North America.

[8]  E. Schoon,et al.  Endoscopic resection for early esophageal carcinoma. , 2019, Journal of thoracic disease.

[9]  Juan Li,et al.  Possible biomarkers for predicting lymph node metastasis of esophageal squamous cell carcinoma: a review , 2019, The Journal of international medical research.

[10]  Dimitrios Schizas,et al.  Can we rely on body mass index when predicting postoperative outcomes and survival of esophageal cancer patients? , 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[11]  T. Underwood,et al.  Molecular pathways in the development and treatment of oesophageal cancer. , 2018, Best practice & research. Clinical gastroenterology.

[12]  Y. Sun,et al.  Long non-coding RNA FAL1 regulated cell proliferation through Akt pathway via targeting PDK1 in esophageal cancer cells. , 2018, European review for medical and pharmacological sciences.

[13]  Yufeng Cheng,et al.  Effects of MiR-210 on proliferation, apoptosis and invasion abilities of esophageal cancer cells. , 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[14]  A. Longatto-Filho,et al.  Angiogenic factors: role in esophageal cancer, a brief review , 2018, Esophagus.

[15]  Kulabutr Komenkul,et al.  Aftermarket Performance of Health Care and Biopharmaceutical IPOs: Evidence From ASEAN Countries , 2017, Inquiry : a journal of medical care organization, provision and financing.

[16]  A. Hölscher,et al.  Current and future treatment options for esophageal cancer in the elderly , 2017, Expert opinion on pharmacotherapy.

[17]  Percy Lee,et al.  The Role of Radiotherapy in Localized Esophageal and Gastric Cancer. , 2017, Hematology/oncology clinics of North America.

[18]  J. Ajani,et al.  Is endoscopic ultrasound examination necessary in the management of esophageal cancer? , 2017, World journal of gastroenterology.

[19]  Sheng-Jie Yu,et al.  Esophageal cancer: Risk factors, genetic association, and treatment. , 2016, Asian journal of surgery.

[20]  M. Arnal,et al.  Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. , 2015 .

[21]  Yingsong 櫻松 Lin 林,et al.  Epidemiology of Esophageal Cancer in Japan and China , 2013, Journal of epidemiology.

[22]  Suyong Choi,et al.  IQGAP1 is a phosphoinositide effector and kinase scaffold. , 2016, Advances in biological regulation.

[23]  María José Domper Arnal,et al.  Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. , 2015, World journal of gastroenterology.

[24]  J. Ajani,et al.  Multidisciplinary therapy for esophageal cancer. , 1990, Advances in surgery.